ZNF350 and breast carcinoma: Meanwhile, overexpression of PFKP may serve as an independent poor prognostic factor for patients with breast cancer, which provides an important basis for targeting PFKP in breast cancer patients with BRCA1 or ZBRK1 deficiency.